Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,257 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Blood Collection Clear all
Completed No phase listed Observational Accepts healthy volunteers

Microgravity Effects on Co-cultured Vascular Cells Types

NCT03144492
View directory record Official record
Conditions
Microgravity Exposed Endothelial Cells
Interventions
Blood volume collected specifically for this study
Biological
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 31, 2026, 2:02 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT00071045
View directory record Official record
Conditions
Neoplasms, Hematologic Neoplasms, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Genetics of Pulmonary Fibrosis

NCT03478553
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Blood draw, Questionnaire
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

NCT04769167
View directory record Official record
Conditions
Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
Interventions
Stool and Blood Specimen Collection, Follow-up Medical Record Review
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional Results available

Role of Neutrophil Activation

NCT01815229
View directory record Official record
Conditions
Patients Requiring Endotracheal Intubation
Interventions
tracheal lavages
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Phase 2 Interventional

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT06839053
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry

NCT07598981
View directory record Official record
Conditions
Obesity
Interventions
Biospecimen collection
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039
View directory record Official record
Conditions
Breast Cancer, Benign Breast Disease
Interventions
Sample collection
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Not yet recruiting Phase 2 Interventional

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

NCT07783581
View directory record Official record
Conditions
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Photon Stereotactic Body Radiation Therapy, Positron Emission Tomography, Spatially-fractionated Radiation Therapy, Surgical Procedure
Procedure · Biological · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting No phase listed Observational

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

NCT03010150
View directory record Official record
Conditions
Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Carcinoma, Metastatic Malignant Neoplasm in the Uterine Cervix, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Early Phase 1 Interventional Results available

Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab

NCT05204290
View directory record Official record
Conditions
Epidural Spinal Tumors, Cancer
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy, Blood draws
Drug · Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT04071223
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant

NCT05540340
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Interventions
Pharmacokinetics
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
304
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Addressing Heavy Alcohol Use Consumption With Kudzu

NCT03709043
View directory record Official record
Conditions
Alcohol Use Disorder, Sexually Transmitted Diseases
Interventions
Standardized kudzu, Placebo, Sexually transmitted infection testing:, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers for recent alcohol use:, Dried Blood Spot (DBS) Testing for PEth:, Behavioral survey measurements:, Ecological Momentary Assessment procedure:
Drug · Other · Diagnostic Test + 1 more
Lead sponsor
Glenn-Milo Santos
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Early Phase 1 Interventional

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

NCT00651976
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Phase 3 Interventional

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

NCT05677490
View directory record Official record
Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
791
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 508 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Immune Reconstitution in Stem Cell Transplant Recipients

NCT02129543
View directory record Official record
Conditions
Cancer
Interventions
Blood Draw
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuronal and Glial Biomarkers in Stroke

NCT02409043
View directory record Official record
Conditions
Stroke
Interventions
Blood draw, Stroke blood draw
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 31, 2026, 2:02 PM EDT